SCHEMBL665304

SCHEMBL665304

O=C(O)Nc1cccc(Cl)c1Cl

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.69
KMT2A Q03164 8/20 0.69
LMNA P02545 3/20 0.66
MAPT P10636 3/20 0.66
NPC1 O15118 1/20 0.60
HPGD P15428 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
MAPK1 P28482 1/20 0.59
GPR35 Q9HC97 1/20 0.57
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
TSHR P16473 1/20 0.55
PDK1 Q15118 1/20 0.54
PDK2 Q15119 1/20 0.54
PDK3 Q15120 1/20 0.54
PDK4 Q16654 1/20 0.54
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL11789630 0.98 MEN1 (0.67) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL10710090 0.85 MEN1 (0.79) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL2094293 0.83 MEN1 (0.69) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL9835974 0.83 MEN1 (0.69) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL2097652 0.83 CYP1A2 (0.62) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL18138901 0.82 MAPT (0.51) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL3612815 0.82 MEN1 (0.67) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL2008072 0.82 MEN1 (1.00) MEN1KMT2ALMNAMAPTNPC1
SCHEMBL2093177 0.82 MAPT (0.71) MEN1KMT2ALMNAMAPTHPGD
SCHEMBL30623497 0.82 MEN1 (0.67) MEN1KMT2ALMNAMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12281104-B2 Process for the production of ethyl 3-amino-1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate through chiral separation of a racemic mixture INTERVET INC. (US) 2025-04-22 US disclosed
US-20220204483-A1 Process for the Production of Ethyl 3-Amino-1-[(3R,4S)-4-Cyanotetrahydropyran-3-YL]pyrazole-4-Carboxylate Through Chiral Separation of a Racemic Mixture INTERVET INC. (US) 2022-06-30 US disclosed
EP-3991835-A1 TRIGLYCERIDE ANALYSIS METHOD, OIL AND FAT SORTING METHOD, AND TRIGLYCERIDE PRODUCTION METHOD The Nisshin OilliO Group, Ltd. (JP) 2022-05-04 EP disclosed
WO-2019194127-A1 METHOD FOR ANALYZING TRIGLYCERIDE, METHOD FOR SEPARATING OIL AND FAT, AND METHOD FOR MANUFACTURING TRIGLYCERIDE 日清オイリオグループ株式会社 2019-10-10 WO disclosed
US-9149791-B2 Water-soluble carbohydrate polyethers TRGel, LLC (US) 2015-10-06 US disclosed
US-8642502-B2 Reversible gel-forming compositions for controlled delivery of bioactive substances TRGel, LLC (US) 2014-02-04 US disclosed
US-20130035310-A1 Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-07 US disclosed
US-20130035310-A1 Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-02-07 US disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20120087891-A1 Reversible Gel-forming Compositions for Controlled Delivery of Bioactive Substances GORKOVENKO ALEXANDER A (US) 2012-04-12 US disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
US-5489387-A Separation agent comprising acyl- or carbamoyl-substituted polysaccharide DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1996-02-06 US disclosed
US-5415780-A Separation agent comprising acyl- or carbamoyl-substituted polysaccharide DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1995-05-16 US disclosed
US-5368737-A Resolution DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1994-11-29 US disclosed
US-5229002-A Separation of optical isomers, cellulose esterified with phenylazobenzoic acid DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1993-07-20 US disclosed
US-5137638-A Mixture of orticla isomers; cellulose tricinnamate DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1992-08-11 US disclosed
US-5075009-A Optical resolution of racemic mixtures using a cellulose tris-4-biphenyl carboxylate DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1991-12-24 US disclosed
US-5017290-A Chromatography DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1991-05-21 US disclosed
US-4966694-A CELLULOSE TRI-BETA-NAPHTHOATE; OPTICAL RESOLUTIONS DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1990-10-30 US disclosed
US-4879038-A Separation agent comprising acyl- or carbamoyl-substituted polysaccharide DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1989-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12281104-B2 Process for the production of ethyl 3-amino-1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate through chiral separation of a racemic mixture CYP3A4, CYP4B1, ACMSD MEN1 4729/4885KMT2A 3906/4885LMNA 4342/4885
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MEN1 4525/4885KMT2A 3324/4885LMNA 4594/4885
US-20130035310-A1 Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels TRPV1, TRPV5, TRPA1 MEN1 4701/4885KMT2A 1129/4885LMNA 4008/4885
US-20120087891-A1 Reversible Gel-forming Compositions for Controlled Delivery of Bioactive Substances PGF, CEL, F12 MEN1 3074/4885KMT2A 4699/4885LMNA 1565/4885
US-20220204483-A1 Process for the Production of Ethyl 3-Amino-1-[(3R,4S)-4-Cyanotetrahydropyran-3-YL]pyrazole-4-Carboxylate Through Chiral Separation of a Racemic Mixture CYP3A4, CYP4B1, ACMSD MEN1 4729/4885KMT2A 3906/4885LMNA 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.